95/190 GHz push-push VCO in 90 nm CMOS

Lin, Yo‐Sheng; Lan, Kai‐Siang; Lin, Yu‐Feng; Lin, Yun-Wen

doi:10.1109/usnc-ursi.2017.8074885

Cited by 3 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few decades, several studies on classical opioid receptors enabled an advanced understanding of how opioid drugs act and exert beneficial and non-desirable effects [72][73][74]. Nevertheless, there is an unmet need for discovering novel opioid analgesics without MOP receptor-associated adverse effects [75][76]. Unlike the MOP receptor agonists, the NOP receptor agonists demonstrate no such non-desirable adverse effects in NHPs, and more importantly, they synergistically enhance MOP receptor agonist-induced analgesia [13,77].…”

Section: Benefits Of Bifunctional Nop/mop Ligandsmentioning

confidence: 99%

“…Unlike the MOP receptor agonists, the NOP receptor agonists demonstrate no such non-desirable adverse effects in NHPs, and more importantly, they synergistically enhance MOP receptor agonist-induced analgesia [13,77]. According to the current literature, ligands with dual NOP and MOP receptor agonist activities can produce potent analgesic effects across different pain modalities and display a much wider therapeutic window when compared with the selective MOP or NOP receptor agonists in NHPs [66,75]. Hence, further research focusing on NOP receptor-related agonists opens a new avenue for developing efficacious and safe analgesics, inducing fewer adverse effects.…”

Section: Benefits Of Bifunctional Nop/mop Ligandsmentioning

confidence: 99%

“…Furthermore, the systemic administration of these NOP full agonists exerted anti-allodynic and anti-hyperalgesic effects in NHPs. NOP full agonists displayed anti-nociception comparable to morphine, while the adverse effects associated with MOP receptor activation were not observed, including respiratory depression, itching, abuse liability, and physical dependence [66,75]. These lines of evidence suggest that the NOP receptor agonists possess potent and safer profiles than clinically used MOP receptor agonists, and are effective for treating pain by systemic administration in primates.…”

Section: Nop Selective Agonistsmentioning

confidence: 99%

“…Notably, selective NOP receptor agonists exert potent anti-nociceptive effects and synergistically enhance the analgesic effects of MOP receptor agonists, while attenuating the drug reinforcing effects in NHPs [66,77]. Given such preferable functional properties of the NOP receptor agonists, it has been hypothesized that the bifunctional NOP/MOP receptor agonists may be safer opioid analgesics, lacking the non-desirable adverse effects, including abuse liability [75]. Based on this hypothesis, a non-morphinan compound, AT-121 (Fig.…”

Section: Bifunctional Nop/mop Partial Agonistsmentioning

confidence: 99%

“…Importantly, buprenorphine shows partial agonist activity for MOP receptors but does not completely lack abuse liability. According to previous reports indicating that an appropriate balance in the NOP/MOP receptor activation displays an ideal pharmacological profile (i.e., potent analgesia without adverse effects) [13,75,77,113], BU08028 was identified as a buprenorphine analog and a bifunctional NOP/MOP receptor agonist [114]. BU08028 (Fig.…”

Section: Bifunctional Nop/mop Partial Agonistsmentioning

confidence: 99%

See 4 more Smart Citations

Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics

Kiguchi

Ding

Kishioka

et al. 2020

CTMC

View full text Add to dashboard Cite

: Despite similar distribution patterns and intracellular events observed in the nociceptin/orphanin FQ peptide (NOP) receptor and other opioid receptors, NOP receptor activation displays unique pharmacological profiles. Several researchers have identified a variety of peptide and non-peptide ligands to determine the functional roles of NOP receptor activation and observed that NOP receptorrelated ligands exhibit pain modality-dependent pain processing. Importantly, NOP receptor activation results in anti-nociception and anti-hypersensitivity at the spinal and supraspinal levels regardless of the experimental settings in non-human primates (NHPs). Given that the NOP receptor agonists synergistically enhance mu-opioid peptide (MOP) receptor agonist-induced anti-nociception, it has been hypothesized that dual NOP and MOP receptor agonists may display promising functional properties as analgesics. Accumulating evidence indicates that the mixed NOP/opioid receptor agonists demonstrate favorable functional profiles. In NHP studies, bifunctional NOP/MOP partial agonists (e.g., AT-121, BU08028, and BU10038) exerted potent anti-nociception via NOP and MOP receptor activation; however, dose-limiting adverse effects associated with the MOP receptor activation, including respiratory depression, itch sensation, physical dependence, and abuse liability, were not observed. Moreover, a mixed NOP/opioid receptor agonist, cebranopadol, presented promising outcomes in clinical trials as a novel analgesic. Collectively, the dual agonistic actions on NOP and MOP receptors, with appropriate binding affinities and efficacies, may be a viable strategy to develop innovative and safe analgesics.

show abstract

Section: Benefits Of Bifunctional Nop/mop Ligandsmentioning

confidence: 99%

Section: Benefits Of Bifunctional Nop/mop Ligandsmentioning

confidence: 99%

Section: Nop Selective Agonistsmentioning

confidence: 99%

Section: Bifunctional Nop/mop Partial Agonistsmentioning

confidence: 99%

Section: Bifunctional Nop/mop Partial Agonistsmentioning

confidence: 99%

See 3 more Smart Citations

Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics

Kiguchi

Ding

Kishioka

et al. 2020

CTMC

View full text Add to dashboard Cite

show abstract

A 95.5-101 GHz Voltage Control Oscillator in 0.13 μm InP HBT

Qiu

et al. 2018

2018 IEEE Asia-Pacific Conference on Antennas and Propagation (APCAP)

View full text Add to dashboard Cite

An Overview of State-of-the-Art D-Band Radar System Components

Stadler

Papurcu

Welling

et al. 2022

Chips

View full text Add to dashboard Cite

In this article, a literature study has been conducted including 398 radar circuit elements from 311 recent publications (mostly between 2010 and 2022) that have been reported mainly in the F-, D- and G-Band (80–200 GHz). This study is intended to give a state-of-the-art comparison on the performance of the different technologies—RFCMOS, SiGe/BiCMOS and III–V semiconductor composites—regarding the most crucial circuit parameters of Voltage-Controlled Oscillators (VCO), Power Amplifiers (PA), Phase Shifters (PS), Low-Noise Amplifiers (LNA) and Mixers. The most common topologies of each circuit element as well as the differences between the technolgies will futher be laid out while reasoning their benefits. Since not all devices were derived solely from single device publications, necessary steps to yield as fairly a comparison as possible were taken. Results include the area and power efficiency in RFCMOS, superior noise and power performance in III–V semiconductors and a continuous compromise between efficiency and performance in SiGe. The most rarely published devices, being Mixers and PSs, in the given frequency range have also been identified to give incentive for further developments.

show abstract

95/190 GHz push-push VCO in 90 nm CMOS

Cited by 3 publications

References 3 publications

Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics

Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics

A 95.5-101 GHz Voltage Control Oscillator in 0.13 μm InP HBT

An Overview of State-of-the-Art D-Band Radar System Components

Contact Info

Product

Resources

About